Skip to Content Skip to Search

Our Respiratory Data Presentations at CHEST 2020

Abstract Name

Study Author

Presentation Details

Benefit–risk profiles of fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus UMEC/VI in patients with chronic obstructive pulmonary disease: a Marko model

MeiLan K. Han, Daniel J. Bratton, Benjamin Hartley, Neil Barnes, Guy Brusselle, Chris Compton, Thomas C. Corbridge, Mark T. Dransfield, David M.G. Halpin, C. Elaine Jones, Paul Jones, Peter Lange, David A. Lipson, Fernando J. Martinez, Alberto Papi, Nicolas Roche, Dave Singh

28684

 

New Insights into COPD and Its Complications

10/21/2020

11:15 am - 12:15 pm

 

 

CAPTAIN Study: Association of moderate and severe asthma exacerbations with lung function and patient-reported outcomes in a large randomized phase III clinical trial

Sule N, Fowler A, Kerstjens HA, Kerwin E, Lee L, Nathan R, Oppenheimer J, Pavord ID, Peachey G, Tabberer M, Zarankaite A, Manning ME, Millard MW, Mannino D, Hanania NA

28281

 

Updates in the Management of Severe Asthma

10/20/2020 2:30-3:30 PM

 

 

Assessment of Patient Interaction With a Dry Powder Inhaler Electronic Medication Monitor and Integrated System Within the Chronic Obstructive Pulmonary Disease Foundation Patient Powered Research Network

Gretchen McCreary, Barbara P. Yawn, John Linnell, Cara B. Pasquale, Elisha Malanga, Radmila Choate, David Stempel, Rahul Gondalia, Leanne Kaye, Kathryn Collison, Richard Stanford, Daniel Gratie, Benjamin Wu, Ryan Tomlinson

P1481

 

 

Risk of death and chronic obstructive pulmonary disease (COPD) hospitalization with fluticasone furoate-containing therapy: Post hoc subgroup analysis from the SUMMIT trial in patients with COPD and a history of exacerbation

Peter M.A. Calverley, Bartolome R. Celli, Courtney Crim, Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, C. Elaine Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, Fernando J. Martinez, Andrea Morris, David E. Newby, Dave Singh, Jørgen Vestbo, Robert Wise, Julie Yates

P1448

 

 

 

 

 

Time-dependent risk of cardiovascular events following an exacerbation in patients with COPD: post hoc analysis from the IMPACT trial

Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, Benjamin Hartley, C. Elaine Jones, Ravi Kalhan, Sally Kilbride, Ken M. Kunisaki, Peter Lange, David A. Lipson, Fernando J. Martinez, Dave Singh, Robert Wise

P1458

 

 

Demographic and clinical characteristics of patients experiencing on-treatment exacerbations, on-treatment death or premature study treatment withdrawal: The IMPACT Trial

Gerard J. Criner, Neil Barnes, Guy Brusselle, Chris Compton, Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, C. Elaine Jones, Mitchell Kaye, Sally Kilbride, Peter Lange, David A. Lipson, Fernando J. Martinez, Alberto Papi, Nicolas Roche, Dave Singh, Robert Wise

P1454

 

 

Single-Inhaler Triple Therapy Fluticasone Furoate/Umeclidinium/Vilanterol Compared With Tiotropium Monotherapy in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis by Airflow Limitation

Antonio Anzueto, Dany Obeid, Sandeep Bansal, Nicola Brown, Chris Compton, Thomas C. Corbridge, David Erb, Catherine Harvey, Morrys C. Kaisermann, Mitchell Kaye, David A. Lipson, Neil Martin, Chang-Qing Zhu, Alberto Papi

P1440

 

 

 

Genetic Variants Do Not Predict Acute COPD Exacerbations or Treatment Response to Fluticasone furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) and its Components

Louise K. Hosking, Astrid J. Yeo, Joshua Hoffman, Mathias N. Chiano, Dana J. Fraser, Soumitra Ghosh, David A. Lipson, Neil Martin, Lynn D. Condreay, Charles J. Cox, Pamela I. St Jean

P1501

 

 

 

 

 

Cross-Sectional Survey to Assess Chronic Obstructive Pulmonary Disease (COPD) Medication use by United States (US) Physicians

David Mannino, James Siddall, Mark Small, Adam Haq, Michael Bogart

P1446

 

 

 

Cross-Sectional Survey to Assess the Burden of Nocturnal Symptoms in Patients with Chronic Obstructive Pulmonary Disease (COPD)

Xavier Soler, James Siddall, Mark Small, Michael Bogart

P1445

 

 

 

Real-World Adherence to Single-Inhaler versus Multiple-Inhaler Triple Therapy among Patients with Chronic Obstructive Pulmonary Disease in a Commercially Insured US Population

Michael Bogart, Benjamin Wu, Guillaume Germain, François Laliberté, Sean MacKnight, Young Jung, Mei Sheng Duh

P1444

 

 

 

 

Prevalence of asthma control and the associated disease burden in US patients with asthma treated with a fixed-dose combination of inhaled corticosteroid and long-acting β2-agonist

Zhang S, White J, Meeraus W, Hinds D, Murali S, Tabberer M, Sansbury L, Fowler A, Lee L, Goolsby Hunter A

P1512

 

 

Views of US pulmonologists on the prevalence of uncontrolled asthma, treatment decisions and the role of treatable traits: results from the CHEST Pulse Surveys

Ramesh N, Hegewald M, Maselli D, Gonzalez E, Lettieri C, Soler X, Lima R, Chang S, Marchetti N

P1488

 

 

CAPTAIN Study: Effect of baseline lung function on response to triple therapy in patients with asthma inadequately controlled on inhaled corticosteroid/long-acting β2-agonist therapy

Nathan R, Boulet L-P, Kerstjens HA, Papi A, Pavord ID, Hanania NA, Oppenheimer J, Maselli DJ, Liu MC, Weinstein S, Mannino D, Peachey G, Zarankaite A, Sule N, Fowler A, Lee L, Kerwin E

P1483

 

 

Reasons why Patients with Severe Asthma Discontinue Biologic Treatment

Silver J, Bogart M, Molfino N, Siddall J, Small M, Hanson M, Hahn B

P0018

 

 

Impact of Mepolizumab in Patients with Life-Threatening Asthma

Silver J, Bogart M, Molfino N, Packnett E, McMorrow D, Wu J, Hahn B

P0017

 

 

Medication Adherence and COPD-Related Costs among Patients with COPD Treated with Umeclidinium/vilanterol (UMEC/VI) versus tiotropium (TIO)

Slade D, Ray R, Moretz C, Germain G,  Laliberte F, Shen Q,  Duh MS, MacKnight S, Hahn B

P1467

 

 

Umeclidinium/vilanterol (UMEC/VI) compared with Tiotropium (TIO) for Time-to-First Inpatient Admission among Patients with Chronic Obstructive Pulmonary Disease in a Managed Care Population

Slade D, Ray R, Moretz C, Germain G,  Laliberte F, Shen Q,  Duh MS, MacKnight S, Hahn B

P1465

 

 

Impact of Umeclidinium/vilanterol (UMEC/VI) versus Tiotropium (TIO), Fluticasone propionate/salmeterol (FP/SAL), and Budesonide/formoterol (B/F) on Time-to-First Severe Exacerbation among Patients with Chronic Obstructive Pulmonary Disease with High Comorbidities and High Costs

Slade D, Ray R, Moretz C, Germain G,  Laliberte F, Shen Q,  Duh MS, MacKnight S, Hahn B

P1466